Another limitation of our study is the lack of validation of proposed mechanisms in pre-clinical in vitro and in vivo models, but we strongly believe that our work generated an in-depth and testable hypothesis regarding mutational exclusivity of ESR1 and TP53 in metastatic ER+ breast cancer, ultimately paving a path for future therapeutic design based on these insights. The gene discussed is TP53; the disease is breast carcinoma.